Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

被引:10
|
作者
Chen, Xiujin [1 ]
Li, Peng [1 ]
Tian, Bin [1 ]
Kang, Xin [1 ]
机构
[1] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthoped, Xian, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
CAR-T; serious adverse events; lymphoma; leukemia; multiple myeloma; solid tumor; CRS; ICANS; CYTOKINE-RELEASE SYNDROME; ACUTE LYMPHOBLASTIC-LEUKEMIA; CARDIOVASCULAR EVENTS; THERAPY; MANAGEMENT; IMMUNOTHERAPY; REMISSIONS; LYMPHOMA; ADULTS; NEUROTOXICITY;
D O I
10.3389/fimmu.2022.1079181
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a variety of solid tumors. Current clinical reports on CAR-T cells in the treatment of malignant tumors are abundant. The tumor-killing activity of CAR-T cells and the unique adverse effects of CAR-T cells have been confirmed by many studies. There is evidence that serious adverse events can be life-threatening. CAR-T cells therapy is increasingly used in clinical settings, so it is important to pay attention to its serious adverse events. In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Irreversible neurotoxicity after CAR-T cells treatment
    Jauvain, M. Martin
    Lucia, N.
    Mehdi, T.
    Clemence, L.
    Marie-Odile, H.
    Dimitri, P.
    Cristina, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 213 - 214
  • [32] Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors
    Yang, Pengxiang
    Yao, Xiaomin
    Tian, Xue
    Wang, Yuehan
    Gong, Leilei
    Yang, Yumin
    Jie, Jing
    MATERIALS TODAY BIO, 2025, 31
  • [33] Strategies to enhance CAR-T persistence
    Yue Liu
    Lingna An
    Ruihao Huang
    Jingkang Xiong
    Haoyu Yang
    Xiaoqi Wang
    Xi Zhang
    Biomarker Research, 10
  • [34] PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
    McGowan, Eileen
    Lin, Qimou
    Ma, Guocai
    Yin, Haibin
    Chen, Size
    Lin, Yiguang
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [35] Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors
    Yuan, Guangxun
    Ye, Mengke
    Zhang, Yixi
    Zeng, Xun
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [36] CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors
    Liu, Jiahao
    Jiao, Xiaofei
    Ma, Ding
    Fang, Yong
    Gao, Qinglei
    MED, 2024, 5 (06): : 530 - 549
  • [37] Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies
    Liu, Yangjie
    Peng, Cao
    Ahad, Faiza
    Zaidi, Syed Aqib Ali
    Muluh, Tobias Achu
    Fu, Qiuxia
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2024, 19 (05) : 557 - 572
  • [38] Late Events After CD-19 CAR-T Treatment
    Hossain, Nasheed M.
    Nishimura, Michael I.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : E1 - E2
  • [39] The CAR-T cells are here
    Croizier, Carolyne
    Douge, Aurore
    Bay, Jacques-Olivier
    Lemal, Richard
    BULLETIN DU CANCER, 2018, 105 (09) : 743 - 745
  • [40] Engineering CAR-T cells
    Zhang, Cheng
    Liu, Jun
    Zhong, Jiang F.
    Zhang, Xi
    BIOMARKER RESEARCH, 2017, 5